drugset / Trial / NCT03692910
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
Timeline
- Start
- 2018-08-23
- Primary completion
- 2019-05-21
- Completion
- 2019-05-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zuranolone | Small molecule | 30 mg | Oral |